European Commission approves Wegovy pill
KEY STEPThe European Commission granted marketing authorization for once daily oral semaglutide 25 mg for weight management in adults with obesity or overweight and a related comorbidity.
Roadmap reference
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manu...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
The European Commission granted marketing authorization for once daily oral semaglutide 25 mg for weight management in adults with obesity or overweight and a related comorbidity.
Roadmap referenceNovo Nordisk began the OASIS 5 phase 3 study to evaluate lower maintenance doses of oral semaglutide for weight management in approximately 450 adults with overweight or obesity.
Roadmap referenceChair of Board
Company leadership profile.
Independent Vice Chair of the Board
Company leadership profile.
Independent Director
Company leadership profile.
Employee Representative Director
Company leadership profile.
Employee Non-Independent Representative Director
Company leadership profile.
Non-Independent Director
Company leadership profile.
Employee Representative Director
Company leadership profile.
Director
Company leadership profile.
Director
Company leadership profile.
Employee Representative Director
Company leadership profile.
Independent Director
Company leadership profile.
Board Observer
Company leadership profile.
Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
Substitute Director
Company leadership profile.
2 experts evaluated Novo Nordisk.
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy